Prospects for a safe COVID-19 vaccine

@article{Haynes2020ProspectsFA,
  title={Prospects for a safe COVID-19 vaccine},
  author={Barton F. Haynes and Lawrence Corey and Prabhavathi Fernandes and Peter B. Gilbert and Peter Jay Hotez and Srinivas Rao and Michael R. Santos and Hanneke Schuitemaker and Michael Watson and Ann M. Arvin},
  journal={Science Translational Medicine},
  year={2020},
  volume={12}
}
Prior vaccine development experiences do not raise concerns about vaccine-associated enhanced disease for COVID-19 vaccine candidates. Rapid development of an efficacious vaccine against the viral pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease 2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions… Expand
Safety and Considerations of the COVID-19 Vaccine Massive Deployment
TLDR
Developing, scaling-up mass production, approval and distribution of COVID-19 vaccines rapidly in this global pandemic setting is challenging as it requires many activities, sequential process with pre-clinical testing, phased clinical trials, planned production, evaluation and followingup surveillance and facesmuch uncertainty. Expand
The Covid-19 Vaccine
To achieve the required level of herd immunity against SARS CoV-2, widespread deployment of COVID-19 vaccine is the best intervention to safeguard against the high mortality, economic disruption, andExpand
SARS-CoV-2 virus: Vaccines in development
TLDR
Current COVID-19 vaccine candidates are examined, their strengths and weaknesses are discussed, published clinical data is summarized, and future challenges are analyzed to analyze future challenges. Expand
Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates
TLDR
A SARS-CoV-2 Spike protein ferritin nanoparticle vaccine, co-formulated with a liposomal adjuvant, elicits broad neutralizing antibody responses that exceed those observed for other major vaccines and rapidly protects against respiratory infection and disease in the upper and lower airways and lung tissue of nonhuman primates. Expand
GRAd-COV2, a gorilla adenovirus based candidate vaccine against COVID-19, is safe and immunogenic in young and older adults
TLDR
Overall, the safety and immunogenicity data from the phase 1 trial support further development of this vaccine. Expand
SARS-CoV-2 vaccines, where do we stand?
Vaccination against the SARS-CoV-2, the virus responsible for the Covid-19 pandemic, represents a major infection control strategy in the absence of effective treatment of the disease to date.Expand
Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants
  • Haitao Liu, Chenliang Zhou, +27 authors Ge Liu
  • Medicine
  • Vaccine
  • 2021
TLDR
Data suggest candidate vaccine is efficacious in preventing SARS-CoV-2 infections and associated pneumonia, thereby justifying ongoing phase I/II clinical studies in China. Expand
COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology
TLDR
The current understanding of COVID-19 is summarised with clinical perspectives, highlighting the association between CO VID-19 and cancer, followed by a vaccine development for this association using nanotechnology, which is suggested to suggest different administration methods for the COvid-19 vaccine formulation options. Expand
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge
TLDR
An immunological signature associated with antiviral protection without disease enhancement following vaccination with research-grade mRNA-1273 is demonstrated. Expand
Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces
  • H. Kwok
  • Medicine
  • International journal of biological sciences
  • 2021
TLDR
A year after the initial outbreak of Covid-19 pandemic, several Phase III clinical trials investigating vaccine safety and efficacy have been published and scientific data available so far for these vaccine candidates for different subgroups of people and different viral variants are discussed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 168 REFERENCES
Development of an inactivated vaccine candidate for SARS-CoV-2
TLDR
Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans. Expand
Rapid COVID-19 vaccine development
TLDR
The benefit of developing an effective vaccine is very high, and even greater if it can be deployed in time to prevent repeated or continuous epidemics. Expand
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
TLDR
It will be essential to depend on careful analysis of safety in humans as immune interventions for COVID-19 move forward, because ADE of disease cannot be reliably predicted after either vaccination or treatment with antibodies. Expand
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
TLDR
Analysis of the vaccine candidates in rhesus macaques showed that animals developed protective humoral and cellular immune responses when challenged with the SARS-CoV-2 virus, suggesting an immune correlate of protection. Expand
Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
TLDR
These SARS-CoV vaccines all induced antibody and protection against infection with SARS -CoV, however, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARsCoV components was induced. Expand
Evaluation of candidate vaccine approaches for MERS-CoV
TLDR
It is shown that immunogens based on full-length S DNA and S1 subunit protein elicit robust serum-neutralizing activity against several MERS-CoV strains in mice and non-human primates. Expand
Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines
TLDR
A scientific working meeting of experts in the field of vaccine immunology and coronaviruses was convened to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. Expand
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
TLDR
The safety and immunogenicity of a SARS DNA vaccine in a Phase I human study was well tolerated and produced cellular immune responses and neutralizing antibody in healthy adults. Expand
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
TLDR
Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. Expand
Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus
TLDR
Inactivated Mers-CoV vaccine appears to carry a hypersensitive-type lung pathology risk from MERS- coV infection that is similar to that found with inactivated SARS-Cov vaccines from SARS -CoV infection. Expand
...
1
2
3
4
5
...